

U.S. Application No. 10/018,964  
 Confirmation No. 6025  
 Amendment dated January 18, 2006

### Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

### Listing of Claims

1. (Currently Amended) An isolated peptide comprising:

~~Tyr-Ser-Gly-Pro-Pro-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Arg-Arg-Xaa<sub>4</sub>-Asn-Xaa<sub>5</sub>-Tyr-Xaa<sub>6</sub> (SEQ ID NO: 1)~~  
 wherein ~~Xaa<sub>1</sub>=Cys or Ser; Xaa<sub>2</sub>=Ser or Gly; Xaa<sub>3</sub>=Ser, Ala or Pro; Xaa<sub>4</sub>=Arg or Gln; Xaa<sub>5</sub>=Ser, Cys or Gly; and Xaa<sub>6</sub>=Asp or Glu~~ Tyr-Ser-Gly-Pro-Pro-Ser-Gly-Ala-Arg-Arg-Arg-Asn-Cys-Tyr-Glu (SEQ ID NO:1);

wherein the isolated peptide does not include a basic helix-loop-helix (bHLH) domain;

wherein the isolated peptide binds cyclin dependent kinase 4.

2. (Canceled)

3. (Currently Amended) A fusion protein comprising:

(a) a peptide comprising ~~Tyr-Ser-Gly-Pro-Pro-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Arg-Arg-Xaa<sub>4</sub>-Asn-Xaa<sub>5</sub>-Tyr-Xaa<sub>6</sub> (SEQ ID NO: 1)~~ wherein ~~Xaa<sub>1</sub>=Cys or Ser; Xaa<sub>2</sub>=Ser or Gly; Xaa<sub>3</sub>=Ser, Ala or Pro; Xaa<sub>4</sub>=Arg or Gln; Xaa<sub>5</sub>=Ser, Cys or Gly; and Xaa<sub>6</sub>=Asp or Glu~~ Tyr-Ser-Gly-Pro-Pro-Ser-Gly-Ala-Arg-Arg-Arg-Asn-Cys-Tyr-Glu (SEQ ID NO:1), wherein the peptide binds cyclin dependent kinase 4; and

(b) a heterologous amino acid sequence.

4. (Original) The fusion protein of claim 3 wherein the heterologous amino acid sequence comprises a nuclear localization signal.

5. (Previously Presented) The fusion protein of claim 4 wherein the peptide is at the C-terminus of the fusion protein.

- 6-7. (Canceled)

U.S. Application No. 10/018,964  
 Confirmation No. 6025  
 Amendment dated January 18, 2006

8. (Withdrawn and Currently Amended) A method of inhibiting cell growth, comprising:  
 administering to a patient a CDK4 binding peptide comprising:

~~Tyr-Ser-Gly-Pro-Pro-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Arg-Arg-Xaa<sub>4</sub>-Asn-Xaa<sub>5</sub>-Tyr-Xaa<sub>6</sub>~~

wherein Xaa<sub>1</sub> = Cys or Ser; Xaa<sub>2</sub> = Ser or Gly; Xaa<sub>3</sub> = Ser, Ala or Pro; Xaa<sub>4</sub> = Arg or Gln; Xaa<sub>5</sub> = Ser, Cys or Gly; and Xaa<sub>6</sub> = Asp or Glu Tyr-Ser-Gly-Pro-Ser-Gly-Ala-Arg-Arg-Asn-Cys-Tyr-Glu (SEQ ID NO:1), wherein the peptide does not include a basic helix-loop-helix domain in an amount effective to inhibit cell growth.

9. (Withdrawn and Currently Amended) A method of inhibiting the activity of CDK4 comprising:

contacting CDK4 with a CDK4 binding peptide comprising:

~~Tyr-Ser-Gly-Pro-Pro-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Arg-Arg-Xaa<sub>4</sub>-Asn-Xaa<sub>5</sub>-Tyr-Xaa<sub>6</sub>~~

wherein Xaa<sub>1</sub> = Cys or Ser; Xaa<sub>2</sub> = Ser or Gly; Xaa<sub>3</sub> = Ser, Ala or Pro; Xaa<sub>4</sub> = Arg or Gln; Xaa<sub>5</sub> = Ser, Cys or Gly; and Xaa<sub>6</sub> = Asp or Glu Tyr-Ser-Gly-Pro-Ser-Gly-Ala-Arg-Arg-Asn-Cys-Tyr-Glu (SEQ ID NO:1), wherein the peptide does not include a basic helix-loop-helix domain in an amount effective to inhibit the activity of CDK4.

10-11. Cancelled.